Maxigen Biotech Inc. (1783.TW)
- Previous Close
42.35 - Open
42.50 - Bid 42.75 x --
- Ask 42.85 x --
- Day's Range
42.50 - 42.95 - 52 Week Range
41.80 - 71.43 - Volume
82,773 - Avg. Volume
164,001 - Market Cap (intraday)
3.806B - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
23.14 - EPS (TTM)
1.85 - Earnings Date --
- Forward Dividend & Yield 0.50 (1.18%)
- Ex-Dividend Date Sep 7, 2023
- 1y Target Est
--
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; and BestAid, a collagen bone graft. It also provides FormaAid, a guided tissue regeneration membrane; HealiAid, a collagen wound dressing product for dental and surgical use; PreviscAid, an ophthalmic viscoelastic device; BiVisc, an ophthalmic viscoelastic system; ViscAid, an ophthalmic viscoelastic device; and dermal filler injections under the Formaderm brand. In addition, the company engages in the manufacturing and sales of beauty care products. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.
mbi-bio.comRelated News
Performance Overview: 1783.TW
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1783.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1783.TW
Valuation Measures
Market Cap
3.77B
Enterprise Value
3.33B
Trailing P/E
22.89
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.09
Price/Book (mrq)
2.77
Enterprise Value/Revenue
5.36
Enterprise Value/EBITDA
15.10
Financial Highlights
Profitability and Income Statement
Profit Margin
26.66%
Return on Assets (ttm)
6.37%
Return on Equity (ttm)
12.48%
Revenue (ttm)
622.12M
Net Income Avi to Common (ttm)
165.83M
Diluted EPS (ttm)
1.85
Balance Sheet and Cash Flow
Total Cash (mrq)
431.08M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
91.4M
Company Insights: 1783.TW
1783.TW does not have Company Insights